June 23, 2025

STING Deletion Attenuates Amyloid Beta Pathology

Genetic deletion of STING in a mouse model of Alzheimer’s disease reduced amyloid plaque accumulation, suppressed neuroinflammatory responses, and improved memory, highlighting STING’s role in disease progression and potential as a therapeutic target.

Conexiant

June 23, 2025

Is HPV-Driven SNSCC Its Own Disease?

Researchers identified key genetic differences between HPV-associated and HPV-independent sinonasal squamous cell carcinoma, revealing distinct mutations, survival risks, and potential treatment targets.

Conexiant

June 23, 2025

Methotrexate Adds No Psoriasis Benefit to Adalimumab

The addition of methotrexate to adalimumab for the treatment of plaque psoriasis may not improve drug survival, efficacy, or safety compared with adalimumab alone, according to a large real-world cohort study.

Conexiant

June 20, 2025

FDA Approves First Twice-Yearly Injectable PrEP

FDA approved the first biannual injectable PrEP option, Yeztugo (lenacapavir), after studies showed it prevented HIV infection in over 99.9% of participants.

Conexiant

June 20, 2025

Multiple Biological Drivers Identified in Hair Graying

New research identifies oxidative stress, DNA damage, genetic variants, and stem cell depletion as key drivers of hair graying, with emerging therapies under investigation.

Conexiant

June 18, 2025

Short on Docs, NPs Fill the Gap

As America’s older adult population grows and geriatricians retire, nurse practitioners are stepping up to provide essential, compassionate care—often in patients’ homes.

KFF Health News

June 17, 2025

FMT as First-Line CDI Treatment?

New randomized trial shows fecal microbiota transplantation may reduce antibiotic dependence in first-episode infections

Conexiant

June 17, 2025

Aconitine Tames Joints, Protects Bone

At EULAR 2025, researchers presented data showing aconitine reduced bone erosion and increased regulatory T cells in a rheumatoid arthritis mouse model.

Conexiant

June 16, 2025

Sacituzumab Govitecan and Pembrolizumab Improve Disease Control in Advanced PD-L1–Positive Triple-Negative Breast Cancer

Results from an international phase III clinical trial show that treatment with sacituzumab govitecan and pembrolizumab helps patients with unresectable, locally advanced or metastatic PD-L1–positive ...

The ASCO Post